clinical trial · NCT07654972
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Eli Lilly and Company·phase1·not yet recruiting·n = 108
ObesityOverweightLY4174794LY4174794Placebo
brief summary
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 35 to 45 weeks (7 to 11 months).
started
Jun 1, 2026
primary completion
Apr 1, 2029
completion
Apr 1, 2029
last updated
Jun 17, 2026
official title
A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol